Compare HKPD & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HKPD | DRMA |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.6M |
| IPO Year | 2024 | 2021 |
| Metric | HKPD | DRMA |
|---|---|---|
| Price | $0.11 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 24.2K |
| Earning Date | 08-07-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.95 |
| 52 Week High | $1.68 | $5.87 |
| Indicator | HKPD | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 28.19 | 36.62 |
| Support Level | $0.10 | $0.95 |
| Resistance Level | $0.70 | $1.40 |
| Average True Range (ATR) | 0.01 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 68.17 | 9.49 |
Cellyan Biotechnology Co Ltd is an integrated pharmaceutical cross-border e-commerce supply chain service provider with a professional team and related pharmaceutical storage facilities in Hong Kong. It operates through two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, referred to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, referred to as the Procurement and Distribution division. Its main business provides one-stop services for merchants engaged in cross-border pharmaceutical e-commerce, including OTC wholesale, import and export, warehousing, packaging, customs clearance and delivery to final destinations, forming a closed loop of pharmaceutical cross-border e-commerce supply chain.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.